MPLT Chief Medical Officer Erin Pennock Foff Sells $124K of Stock

MapLight Therapeutics, Inc. MPLT saw insider selling activity as its Chief Medical Officer, Erin Pennock Foff, parted with company stock. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the transaction took place in the middle of October.

Inside Erin Pennock Foff's MapLight Therapeutics Trade

Erin Pennock Foff disposed of 15,355 shares of MapLight Therapeutics on October 15, 2026. The shares were sold at a price of $8.08 each, bringing the total value of the transaction to approximately $124,068. The stock closed at $8.02 on the day of the trade. This sale was not executed under a pre-arranged Rule 10b5-1 trading plan.

Other Institutional Activity in MapLight Therapeutics

Large financial institutions hold substantial positions in the clinical-stage biotech firm. Novo Holdings A/S held 3,686,622 shares valued at about $28,386,988 as of June 30, 2026, making no change to its stake. FCPM III Services B.V. maintained 3,226,400 shares worth roughly $24,843,279. Nan Fung Group Holdings Limited held 971,253 shares valued at $7,478,647, while 5AM Venture Management, LLC kept 950,111 shares worth about $7,315,084. Sanofi rounded out the group with 912,041 shares valued at $7,022,715, with none of these major institutional holders adjusting their share counts during the reporting period.

MapLight Therapeutics, Inc. Stock Down 3.9%

The shares recently traded around $7.11 as of October 16, 2026, sitting below the event-day close and well under the company's 52-week high of $40.43. The equity hovers not far above its 52-week low of $7.46.

Recent Earnings

The company posted trailing twelve-month earnings per share of -$6.25, alongside a return on equity of -111.5%. The biotech firm holds a net margin of 0.0% and prepares to release its next set of financial results on November 12, 2026.

Insider Buying and Selling at MapLight Therapeutics, Inc.

Other insiders have transacted in MPLT stock in recent months. Director Troy M. Cox bought 15,620 shares at $12.31 per share on July 28, 2026, totaling $192,282. Beneficial owner Catalyst4, Inc. purchased 1,209,225 shares on July 30, 2026, and later acquired another 4,400,000 shares at $11.38 on August 14, 2026, for roughly $50,072,000. Meanwhile, officer James Woodruff Lillie sold 22,082 shares at $12.54 on August 3, 2026, for a total of $276,908.

Analysts Set New Price Targets

Wall Street firms have adjusted their stances on the clinical-stage biotech firm over the summer and fall. Canaccord Genuity maintained its buy rating on July 28, 2026, while lowering its price target from $43 to $24. On the same day, Morgan Stanley downgraded the stock to equal-weight and trimmed its target from $34 to $21. UBS followed with a downgrade to neutral on August 10, 2026, slashing its target from $52 to $13. Later in the month, Needham reiterated a buy rating on August 31, 2026, adjusting its target slightly from $45 to $43. Guggenheim initiated coverage with a neutral rating on October 6, 2026. Overall, MapLight Therapeutics carries a consensus strong buy rating and a mean price target of $26.54 across 13 analyst opinions.

About MapLight Therapeutics

MapLight Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel treatments for patients suffering from debilitating central nervous system disorders. Headquartered in Redwood City, California, the firm employs 133 people and advances targeted therapeutics backed by its clinical pipeline.

Bottom Line

Investors will watch for the upcoming earnings report on November 12, 2026, to gauge pipeline updates and financial progress. Regulatory filings and further insider transactions will continue to provide visibility into management and institutional sentiment.